Scherm­afbeelding 2025 08 22 om 12.47.49

DEBRA Research forms strategic alliance with Queen Mary University to accelerate epidermolysis bullosa therapeutics

Global nonprofit DEBRA Research has established a preclinical research collaboration with Queen Mary University of London to enhance drug development capabilities for epidermolysis bullosa, addressing critical bottlenecks in therapeutic advancement for this rare genetic skin disorder through innovative academic-philanthropic partnership models.

4basebio lab

Synthetic DNA manufacturer 4basebio rebrands as part of therapeutic expansion

Cambridge-based 4basebio has launched refreshed branding and a new website following its £40 million investment round, as the AIM-listed company positions itself for growth in synthetic DNA manufacturing for next-generation therapeutics including gene therapy, RNA therapeutics and vaccine development.

Cherwell Renamed AnalytiChem UK

Cherwell Laboratories completes strategic integration as AnalytiChem UK

Cherwell Laboratories, the established cleanroom microbiology specialist will transition to AnalytiChem UK from September 2025, marking the completion of its integration with the global AnalytiChem Group whilst maintaining its 54-year heritage in pharmaceutical manufacturing support and quality control solutions.

ARTBIO Emanuele Ostuni

ARTBIO secures $132 million series B funding for alpha radioligand therapy advancement

Clinical-stage radiopharmaceutical company ARTBIO has completed a substantial $132 million Series B financing round to advance its pipeline of alpha radioligand therapies, expand manufacturing capabilities, and support Phase II development of lead candidate AB001 for metastatic castration-resistant prostate cancer.

GEA

GEA advances freeze-drying manufacturing with €80 million pharmaceutical technology centre

GEA’s new 40,000-square-metre facility in Elsdorf, Germany represents a strategic expansion into pharmaceutical freeze-drying systems, addressing surging global demand for vaccine and injectable drug manufacturing technologies. The investment demonstrates significant industry confidence in lyophilisation technology advancement.

shimadzu150years

Shimadzu Corporation

Advancing clinical diagnostics through analytical excellence

i20 Lid OnlyFullyOpen V01

EUROIMMUN | United expertise for ChLIA diagnostics

Automated chemiluminescence immunoassay (ChLIA) systems are nowadays a mainstay for many diagnostic laboratories. Euroimmun has joined forces with Immunodiagnostic Systems (IDS) to offer an extensive portfolio of diagnostic solutions based on ChLIA technology. Clinical Laboratory International talked to Dr. Anna Stanisak, Global Product Manager for Automation at Euroimmun to find out more.

AdobeStock 884707147

Dedication to external quality assessment was recognized and rewarded at this year’s LabMedUK meeting

Congratulations to Finlay MacKenzie and Dr Rachel Marrington of Birmingham Quality [one of the main providers of clinical biochemistry external quality assessment (EQA) schemes in the UK] on receipt of their Impact Award presented at this year’s LabMedUK meeting in Manchester. This prestigious award recognizes their outstanding work on patient-centric EQA for acute kidney injury […]

Scherm­afbeelding 2025 08 21 om 12.55.46

DiaSys Diagnostic Systems

A global leader in liquid-stable reagents

werfen logo

Werfen

Pioneering next-generation clinical diagnostics through innovation and sustainability